In an effort to foster innovation, the U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 Prioritized Examination Pilot Program.
In an effort to foster innovation, the U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 Prioritized Examination Pilot Program. To qualify, the claim(s) of an application must cover a product or process related to COVID-19, and the product or process must be subject to an applicable FDA approval for COVID-19 use. The pilot is limited to applicants that qualify for either small or micro entity status, including small businesses and individual inventors.
Patents that are fast-tracked through the program could reach a final decision in as fast as six months. In addition, qualifying applicants will not need to pay the USPTO’s typical prioritized examination fees.
“Independent inventors and small businesses are often the difference-makers when it comes to cutting-edge innovation and the growth of our economy,” Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the USPTO said in a press statement. “They are also in most need of assistance as we fight this pandemic. Accelerating examination of COVID-19-related patent applications, without additional fees, will permit such innovators to bring important and possibly life-saving treatments to market more quickly.”
Prioritized Examination
Typically, the USPTO examines new patent applications in the order of their U.S. filing dates. However, the agency has several programs under which eligible patent applications can be advanced out of turn.
The new COVID-19 Prioritized Examination Pilot Program will provide prioritized examination without payment of the additional fees for prioritized examination for certain applications that claim products or processes that are subject to an applicable FDA approval for COVID-19 use. According to the USPTO, such approvals may include, but are not limited to, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), a New Drug Application (NDA), a Biologics License Application (BLA), a Premarket Approval (PMA), or an Emergency Use Authorization (EUA).
The goal of prioritized examination is to provide a final disposition within 12 months, on average, from the date the prioritized status has been granted. However, the USPTO believes it can achieve final disposition in six months if applicants provide more timely responses to notices and actions from the USPTO.
Eligibility Requirements As set forth in the USPTO’s Federal Register Notice, patent applicants seeking to take advantage of the pilot program must satisfy several eligibility requirements. The request for prioritized examination under the pilot program must be made:
With the filing of a non-continuing original utility or plant nonprovisional application;
With the filing of an original utility or plant nonprovisional application claiming the benefit of an earlier filing date under 35 U.S.C. 120, 121, or 365(c) of one prior nonprovisional application or one prior international application designating the United States; or
With or after the filing of a request for continued examination (RCE) of such plant or utility application or of a national stage of an international application. Consistent with 37 CFR l.102(e)(2), only a single request for prioritized examination filed with or after filing an RCE may be granted in an application.
The pilot program is reserved for the above nonprovisional applications. Accordingly, any application that claims the benefit of the filing date of two or more prior-filed nonprovisional U.S. applications or international applications designating the United States under 35 U.S.C. 120, 121, or 365(c) is not eligible for participation under the pilot program.
Act Fast: The Pilot Program Limits the Number of Requests
The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination until the USPTO has accepted a total of 500 requests. According to the USPTO, it may extend the pilot program (with or without modifications) or terminate it depending on the “workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program.”
If you have questions, please contact us
If you have any questions or if you would like to discuss the matter further, please contact me, Libby Varghese, or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.
How the Courts Are Reacting to COVID-19 Contract Cases
Breach of contract cases arising out of the COVID-19 pandemic are slowly making their way through the court system… Breach of contract cases arising out of the coronavirus (COVID-19) pandemic are slowly making their way through the court system. The early decisions shed light on how courts are handling force majeure provisions and contract defenses […]
What to Know About USPTO COVID-19 Prioritized Trademark Examination Program
The USPTO recently announced a new COVID-19 prioritized examination program for certain trademark and service mark applications… The U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 prioritized examination program for certain trademark and service mark applications. It is available for products that are subject to U.S. Food and Drug Administration (FDA) approval […]
After a difficult few months, New Jersey restaurants are gradually reopening their doors for on-premises dining. After a difficult few months, New Jersey restaurants are gradually reopening their doors for on-premises dining. For restaurant operators and their customers, it is important to understand what is required to reopen safely. This article outlines the guidance provided […]
The Regulatory Examination Process has evolved in positive directions over the past several years. Thanks to these prior process improvements, the SEC, CFTC/NFA and FINRA are able to conduct regulatory exams virtually… The Regulatory Examination Process has clearly evolved in positive directions over the past several years. Thanks in part to these prior process improvements, […]
Understanding the Risks and Benefits of Remote Legal Proceedings
The coronavirus (COVID-19) pandemic has forced us to change the way we conduct everyday activities… The coronavirus (COVID-19) pandemic has forced us to change the way we conduct everyday activities. Court proceedings, arbitrations, and mediations are no exception, and parties to such proceedings increasingly rely on video conferencing to go “virtual.” While technology can allow […]
Will COVID-19 Prompt an Uptick in White-Collar Crime Investigations?
While the COVID-19 pandemic may be slowing the pace at which white-collar crimes are prosecuted, it would be unwise to expect that the pace of white-collar investigations will slow… While the coronavirus (COVID-19) pandemic may be slowing the pace at which white-collar crimes are prosecuted, it would be unwise to expect that the pace of […]
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Sign up to get the latest from our attorneys!
Explore What Matters Most to You.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
How to Take Advantage of the USPTO’s COVID-19 Prioritized Examination Pilot Program
Author: Libby Babu Varghese
In an effort to foster innovation, the U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 Prioritized Examination Pilot Program.
In an effort to foster innovation, the U.S. Patent and Trademark Office (USPTO) recently announced a new COVID-19 Prioritized Examination Pilot Program. To qualify, the claim(s) of an application must cover a product or process related to COVID-19, and the product or process must be subject to an applicable FDA approval for COVID-19 use. The pilot is limited to applicants that qualify for either small or micro entity status, including small businesses and individual inventors.
Patents that are fast-tracked through the program could reach a final decision in as fast as six months. In addition, qualifying applicants will not need to pay the USPTO’s typical prioritized examination fees.
“Independent inventors and small businesses are often the difference-makers when it comes to cutting-edge innovation and the growth of our economy,” Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the USPTO said in a press statement. “They are also in most need of assistance as we fight this pandemic. Accelerating examination of COVID-19-related patent applications, without additional fees, will permit such innovators to bring important and possibly life-saving treatments to market more quickly.”
Prioritized Examination
Typically, the USPTO examines new patent applications in the order of their U.S. filing dates. However, the agency has several programs under which eligible patent applications can be advanced out of turn.
The new COVID-19 Prioritized Examination Pilot Program will provide prioritized examination without payment of the additional fees for prioritized examination for certain applications that claim products or processes that are subject to an applicable FDA approval for COVID-19 use. According to the USPTO, such approvals may include, but are not limited to, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), a New Drug Application (NDA), a Biologics License Application (BLA), a Premarket Approval (PMA), or an Emergency Use Authorization (EUA).
The goal of prioritized examination is to provide a final disposition within 12 months, on average, from the date the prioritized status has been granted. However, the USPTO believes it can achieve final disposition in six months if applicants provide more timely responses to notices and actions from the USPTO.
Eligibility Requirements As set forth in the USPTO’s Federal Register Notice, patent applicants seeking to take advantage of the pilot program must satisfy several eligibility requirements. The request for prioritized examination under the pilot program must be made:
With the filing of a non-continuing original utility or plant nonprovisional application;
With the filing of an original utility or plant nonprovisional application claiming the benefit of an earlier filing date under 35 U.S.C. 120, 121, or 365(c) of one prior nonprovisional application or one prior international application designating the United States; or
With or after the filing of a request for continued examination (RCE) of such plant or utility application or of a national stage of an international application. Consistent with 37 CFR l.102(e)(2), only a single request for prioritized examination filed with or after filing an RCE may be granted in an application.
The pilot program is reserved for the above nonprovisional applications. Accordingly, any application that claims the benefit of the filing date of two or more prior-filed nonprovisional U.S. applications or international applications designating the United States under 35 U.S.C. 120, 121, or 365(c) is not eligible for participation under the pilot program.
Act Fast: The Pilot Program Limits the Number of Requests
The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination until the USPTO has accepted a total of 500 requests. According to the USPTO, it may extend the pilot program (with or without modifications) or terminate it depending on the “workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program.”
If you have questions, please contact us
If you have any questions or if you would like to discuss the matter further, please contact me, Libby Varghese, or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.
Let`s get in touch!
Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!
